Elanco Animal Health Incorporated

NYSE:ELAN

Drug Manufacturers - Specialty & Generic

Healthcare
$26.70 -3.47%

-$0.84 today

Market cap
$13.35B
Beta
1.70
P/E (TTM)
-48.1
EPS (TTM)
-$0.49
52W Low $13.16High $27.72

Volume 5.78M

Average 6.04M

ELAN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Elanco Animal Health IncorporatedNYSE: ELAN

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 506.5M shares rose 2.0% year over year, ahead of the +1.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
506.5M+0.1% QoQ
Last fiscal yearDec 2025
496.4M-0.2% YoY
LTMSep 2026
503.83M+1.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year-0.2%——
3-year CAGR+0.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
496.4M USD
Year-over-year change
-0.2%
4-year CAGR
+0.5%

Weighted Avg Shares (Diluted) vs competitors

How ELAN compares with its peers on the latest reported figures

  • ELAN's LTM Sep 2026 weighted avg shares (diluted) of 503.83M shares is the 2nd highest of the 6 companies compared; the peer median is 217.73M shares.
  • Its year-over-year change of +1.3% is the highest of 6, against a peer median of -1.6%.
  • Over three fiscal years its annual growth of +0.5% compares with a peer median of -0.5%.
ELAN Competitors Peer median
Weighted Avg Shares (Diluted) for ELAN and competitors
Company Period LTM YoY 3-year CAGR
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
ELANElanco Animal Health IncorporatedLTM Sep 2026503.83M +1.3%+0.5%
ZTSZoetis Inc.LTM Jun 2026430.48M -4.2%-1.9%
NEOGNeogen CorporationLTM Aug 2026217.73M +0.3%+4.8%
IDXXIDEXX Laboratories, Inc.LTM Sep 202680.27M -1.6%-1.6%
PAHCPhibro Animal Health CorporationLTM Mar 202640.89M +0.6%+0.2%
Peer median (excluding ELAN) 217.73M-1.6%-0.5%

Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.76B4.41B4.42B4.44B4.72B
Cost of Revenue2.69B2.44B2.48B2.53B2.67B
Gross Profit2.08B1.97B1.94B1.91B2.05B
Gross Margin43.6%44.7%43.9%43.0%43.5%
Research & Development369M321M327M344M368M
Selling, General & Admin1.4B1.27B1.29B1.31B1.43B
Operating Expenses1.77B1.59B1.61B1.66B1.8B
Depreciation & Amortization716M682M694M662M680M
EBITDA409M866M(224M)1.49B676M
EBITDA Margin8.6%19.6%-5.1%33.5%14.3%
Operating Income304M384M326M251M252M
Operating Margin6.4%8.7%7.4%5.7%5.3%
Interest Income000045M
Interest Expense264M256M277M339M220M
Other Income / Expenses(875M)(456M)(1.52B)237M(476M)
Income Before Tax(571M)(72M)(1.2B)488M(224M)
Pre-Tax Margin-12.0%-1.6%-27.1%11.0%-4.8%
Income Tax Expense(88M)6M36M150M8M
Net Income(483M)(78M)(1.23B)338M(232M)
Net Margin-10.1%-1.8%-27.9%7.6%-4.9%
EPS (Basic)(0.97)(0.15)(2.50)0.68(0.47)
EPS (Diluted)(0.97)(0.15)(2.50)0.68(0.47)
Weighted Avg Shares487.2M488.3M492.3M494M496.4M
Weighted Avg Shares (Diluted)487.2M488.3M492.3M497.3M496.4M

Elanco Animal Health Incorporated

NYSE:ELAN

Intrinsic Alpha fair value

Locked

Current Price

$26.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.